) recently announced that its epinephrine injection, Allerject,
is available in Canada for the emergency treatment of
anaphylactic reactions in patients at risk or with a history of
anaphylaxis. Allerject is a unique epinephrine auto-injector,
which guides the patients and physicians through each step of the
injection process with the help of audio instructions.
We note that Allerject is approved in the US under the brand
name Auvi-Q. Currently, epinephrine is the only first-line
treatment for anaphylaxis.
) currently have an agreement for EpiPen auto-injector. While
Pfizer manufactures the product, Mylan is responsible for its
marketing. The EpiPen Auto-injector is the best prescribed
treatment for severe allergic reactions with a US market share of
We remind investors that several of Sanofi's candidates will
be up for approval in the coming quarters. The French pharma
giant expects regulatory decisions in the EU on Zaltrap
(aflibercept) for second-line metastatic colorectal cancer and
Lyxumia (lixisenatide) for type II diabetes by Mar 31, 2013.
Moreover, a decision from the US Food and Drug Administration
(FDA) regarding Lyxumia's new drug application (NDA) is expected
Sanofi expects the FDA to give a final decision on its
candidate, Kynamro (mipomersen) for treating patients suffering
from homozygous familial hypercholesterolemia, by Jan 29,
We are pleased with Sanofi's efforts to develop its pipeline,
which should make significant revenue contributions upon
approval. However, we note that Sanofi's biggest challenge is the
generic threat that is faced by several of its products.
Sanofi carries a Zacks Rank #2 (Buy) in the short run.
), carrying a Zacks Rank #1 (Strong Buy), currently looks more
attractive in the pharma space.
MYLAN INC (MYL): Free Stock Analysis Report
PFIZER INC (PFE): Free Stock Analysis Report
SANOFI-AVENTIS (SNY): Free Stock Analysis
To read this article on Zacks.com click here.